Home › Companies › DFTX

Definium Therapeutics

DFTX Lead: Phase 3 ★ Read the deep dive → 6 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (4 active programs)

lysergide tartrate

DT120 · DT120 ODT

Small Molecule Target: 5-HT2A

Generalized Anxiety Disorder Phase 3 oral
Posttraumatic Stress Disorder Phase 3 oral

lysergide tartrate

lysergide · DT120 · DT120 ODT

Small Molecule Target: 5-HT2A

Major Depressive Disorder Phase 3 oral

R(-)-MDMA

DT402

Autism Spectrum Disorder Phase 2

Biotech Distilled coverage (6)

2026-06-24 UPDATE: Definium (DFTX) - The Raise Got Upsized, And The Greenshoe Cleared Same-Day
2026-06-22 UPDATE: Definium (DFTX) - Emerge Hits, And They Hit the Market
2026-05-08 UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party 🔒 Paid
2026-04-27 UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper 🔒 Paid
2026-02-28 UPDATE: Definium (DFTX) Q4 Financial Update 🔒 Paid
2026-01-14 Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.